mRNA and protein expression of leukotriene B4 receptor 2 during transition from colitis to colon cancer
10.13220/j.cnki.jipr.2014.05.014
- Author:
Chun-Guang HAN
1
Author Information
1. Institute of Radiation Medicine, Academy of Military Medical Sciences
- Publication Type:Journal Article
- Keywords:
Colitis;
Colon cancer;
Leukotriene B4 receptor 2
- From:
Journal of International Pharmaceutical Research
2014;41(5):580-584
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe mRNA and protein expression of leukotriene B4 (LTB4) receptor 2 (BLT2)in mice during the course of development from colitis to colitis-associated cancer. Methods: ICR mice were used to establish the animal model of colitis-associated colon cancer and randomly divided into control group and experimental group. We began to administer inducer on d0. Mice were sacrificed at 2, 3, 5, 7, 9, 13, and 18w, respectively. Histopathological changes in colons were examined. The protein and mRNA expression of BLT2 in colons were measured by immunohistochemical assay and real-time quantitative PCR, respectively. Results: Histological study showed that with the extension of time, the lesions of mice colons aggravated, first a mild inflammation, then atypical hyperplasia, and finally to colon cancer. Immunohistochemical staining showed that the expression of BLT2 protein was low in normal colon, but high in inflammatory lesions, especially in inflammatory cells. There was no BLT2 expression in atypical hyperplasia and cancer cells, while BLT2 was highly expressed in the stroma and lumans of cancer tissue. Compared with the control group, mRNA expression of BLT2 in the experimental group was significantly higher at 2, 13 and 18w (P<0.05); and very significantly higher at 3, 5, 7 and 9w(P<0.01). Conclusion: The mouse model of colitis-associated colon cancer was developed in this study. The expression of BLT2 changed in the course of colitis development, indicating that BLT2 may play an important role in the transition process from colitis to colon cancer.
